AR101262A1 - Plataforma de purificación para anticuerpos biespecíficos - Google Patents
Plataforma de purificación para anticuerpos biespecíficosInfo
- Publication number
- AR101262A1 AR101262A1 ARP150102301A ARP150102301A AR101262A1 AR 101262 A1 AR101262 A1 AR 101262A1 AR P150102301 A ARP150102301 A AR P150102301A AR P150102301 A ARP150102301 A AR P150102301A AR 101262 A1 AR101262 A1 AR 101262A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- domain
- binding
- paired
- ablation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3819—Affinity chromatography of the nucleic acid-nucleic acid binding protein type
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/26—Cation exchangers for chromatographic processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Una cromatografía de la proteína A de alta resolución que emplea un agente caotrópico y un gradiente de pH o un tampón de elución del paso de pH resulta en una resolución pico mejorada entre las especies moleculares estrechamente relacionadas. Los anticuerpos biespecíficos que contienen un dominio CH3 con sustitución de ablación de unión a la proteína A emparejado con un dominio CH3 de unión a proteína A se separan con una resolución de pico alto de los anticuerpos monoespecíficos que contienen un dominio CH3 sustituido por ablación de unión a la proteína A emparejado con el dominio CH3 sustituido con ablación de unión de proteína A y anticuerpos monoespecíficos que contienen un dominio CH3 de unión a la proteína A emparejado con el dominio CH3 de unión a la proteína A. Los agentes caotrópicos útiles incluyen cloruro de magnesio y cloruro de calcio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029463P | 2014-07-26 | 2014-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101262A1 true AR101262A1 (es) | 2016-12-07 |
Family
ID=53836215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102301A AR101262A1 (es) | 2014-07-26 | 2015-07-21 | Plataforma de purificación para anticuerpos biespecíficos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10626142B2 (es) |
| EP (2) | EP3912987B9 (es) |
| JP (1) | JP6702967B2 (es) |
| KR (1) | KR102440737B1 (es) |
| CN (1) | CN107074906B (es) |
| AR (1) | AR101262A1 (es) |
| AU (1) | AU2015298156B2 (es) |
| DK (2) | DK3172221T3 (es) |
| EA (1) | EA036154B1 (es) |
| ES (2) | ES2881026T3 (es) |
| FI (1) | FI3912987T3 (es) |
| IL (1) | IL255198B (es) |
| MX (1) | MX377558B (es) |
| MY (1) | MY187051A (es) |
| PL (2) | PL3912987T3 (es) |
| SG (2) | SG10201900661YA (es) |
| TW (1) | TWI704155B (es) |
| WO (1) | WO2016018740A2 (es) |
| ZA (1) | ZA201700622B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
| IN2014DN10515A (es) | 2006-03-31 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | |
| MX336725B (es) | 2007-09-26 | 2016-01-28 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| DK3059246T3 (en) | 2007-09-26 | 2018-10-01 | Chugai Pharmaceutical Co Ltd | Modified constant region of an antibody |
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| EP3549606A1 (en) * | 2015-05-28 | 2019-10-09 | Bio-rad Laboratories, Inc. | Affinity ligands and methods relating thereto |
| CA3004288C (en) * | 2015-12-28 | 2025-05-27 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION |
| AU2017255077B2 (en) | 2016-04-28 | 2024-05-16 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| WO2017194593A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| CN109311949B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 储存分离基质的方法 |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| ES2988363T3 (es) * | 2016-06-17 | 2024-11-20 | Hoffmann La Roche | Purificación de anticuerpos multiespecíficos |
| KR101933656B1 (ko) | 2016-08-20 | 2018-12-28 | (주) 아이벤트러스 | 목적하는 이중특이성 항체의 선택적 생산 확인 방법 |
| WO2018038469A1 (ko) * | 2016-08-20 | 2018-03-01 | (주)아이벤트러스 | 목적하는 이중특이성 항체의 선택적 생산 확인 방법 |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| BR112020008393A2 (pt) | 2017-11-01 | 2020-11-03 | Chugai Seiyaku Kabushiki Kaisha | variante e isoforma de anticorpos com atividade biológica reduzida |
| WO2019183334A1 (en) | 2018-03-21 | 2019-09-26 | Waters Technologies Corporation | Non-antibody high-affinity-based sample preparation, sorbents, devices and methods |
| GB201805142D0 (en) * | 2018-03-29 | 2018-05-16 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US12152056B2 (en) | 2018-08-17 | 2024-11-26 | Regeneron Pharmaceuticals, Inc. | Method and chromatography system for determining amount and purity of a multimeric protein |
| BR112021004680A2 (pt) * | 2018-09-21 | 2021-08-31 | Teneobio, Inc. | Métodos para purificar anticorpos multiespecíficos heterodiméricos |
| JPWO2020066270A1 (ja) * | 2018-09-28 | 2021-08-30 | 株式会社カネカ | κ鎖可変領域を含む抗体および／または抗体断片の製造方法 |
| EP3874276B1 (en) | 2018-10-31 | 2023-09-06 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
| AU2019384790A1 (en) * | 2018-11-21 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Anti-staphylococcus antibodies and uses thereof |
| US20220009959A1 (en) * | 2018-11-26 | 2022-01-13 | North Carolina State University | Peptide ligands for capture of host cell proteins |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| BR112021012337A2 (pt) | 2018-12-24 | 2021-09-14 | Sanofi | Proteínas de ligação multiespecíficas baseadas em pseudofab |
| CN113966343A (zh) | 2019-06-11 | 2022-01-21 | 瑞泽恩制药公司 | 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法 |
| US12545702B2 (en) * | 2019-06-13 | 2026-02-10 | Regeneron Pharmaceuticals, Inc. | Methods for removing undesired components during multistage chromatographic processes |
| EP3931303A1 (en) | 2019-12-06 | 2022-01-05 | Regeneron Pharmaceuticals, Inc. | Anti-vegf protein compositions and methods for producing the same |
| BR112022011993A2 (pt) * | 2019-12-26 | 2022-09-20 | Abl Bio Inc | Método para purificar peptídeo biologicamente ativo usando cromatografia de afinidade de proteína a |
| KR102834449B1 (ko) | 2019-12-27 | 2025-07-15 | 케이에스광학주식회사 | 투명한 방탄 적층 구조물 |
| WO2021226444A2 (en) | 2020-05-08 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Vegf traps and mini-traps and methods for treating ocular disorders and cancer |
| JP2024504388A (ja) * | 2021-01-25 | 2024-01-31 | ユーハン・コーポレイション | 抗４－１ｂｂ／抗ｈｅｒ２二重特異性抗体の精製方法 |
| GB202109246D0 (en) * | 2021-06-28 | 2021-08-11 | Cytiva Bioprocess R & D Ab | A method of separating bispecific antibodies |
| JP2024539136A (ja) * | 2021-10-19 | 2024-10-28 | アルテオジェン・インコーポレイテッド | ＩｇＧ Ｆｃドメインを有する融合タンパク質の精製方法 |
| CN119403839A (zh) * | 2022-06-22 | 2025-02-07 | 思拓凡生物工艺研发有限公司 | κ轻链结合对流基质 |
| WO2024123698A1 (en) | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
| CN116769044A (zh) * | 2023-07-11 | 2023-09-19 | 康日百奥生物科技(苏州)有限公司 | 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法 |
| WO2025073922A1 (en) * | 2023-10-04 | 2025-04-10 | Sartorius Bia Separations D.O.O. | Enhanced chromatographic separations of components in a mixture by employing chaotropic elution |
| US20250163468A1 (en) | 2023-11-21 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
| WO2025131519A1 (en) * | 2023-12-21 | 2025-06-26 | Cytiva Bioprocess R&D Ab | Antibody separation with a vh3 binding separation matrix |
| WO2025173342A1 (ja) * | 2024-02-13 | 2025-08-21 | Jsr株式会社 | Ｆｃ融合タンパク質を精製するためのクロマトグラフィー用担体、及びそれを用いたＦｃ融合タンパク質の精製方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8626412D0 (en) | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| GB8626413D0 (en) | 1986-11-05 | 1986-12-03 | Gilliland L K | Antibodies |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5945311A (en) | 1994-06-03 | 1999-08-31 | GSF--Forschungszentrumfur Umweltund Gesundheit | Method for producing heterologous bi-specific antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0826695B1 (de) | 1996-09-03 | 2001-12-12 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern |
| DK0826696T3 (da) | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| DE19725586C2 (de) | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
| ES2212638T3 (es) | 1998-09-25 | 2004-07-16 | Lindhofer, Horst, Dr. | Utilizacion de celulas tumorales en tiempo escalonado en combinacion con anticuerpos intactos para la inmunizacion. |
| US20030224000A1 (en) | 2001-12-21 | 2003-12-04 | Kokai-Kun John Fitzgerald | Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| US7169903B2 (en) | 2001-12-21 | 2007-01-30 | Biosynexus Incorporated | Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria |
| PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
| ES2402650T3 (es) | 2005-06-17 | 2013-05-07 | Janssen Alzheimer Immunotherapy | Métodos de purificación de anticuerpos anti A beta |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
| SG149759A1 (en) * | 2007-07-10 | 2009-02-27 | Millipore Corp | Media for affinity chromatography |
| US20110166332A1 (en) * | 2008-09-12 | 2011-07-07 | Ge Healthcare Bio-Sciences Ab | Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| KR101747103B1 (ko) * | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| RU2606264C2 (ru) * | 2009-12-25 | 2017-01-10 | Чугаи Сеияку Кабушики Каиша | Способ полипептидной модификации для очистки полипептидных мультимеров |
| PT3434767T (pt) * | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| EP2500073A1 (en) * | 2011-03-17 | 2012-09-19 | ChromaCon AG | Method for identification and purification of multi-specific polypeptides |
| EP2825559B1 (en) * | 2012-03-13 | 2019-02-27 | Novimmune SA | Readily isolated bispecific antibodies with native immunoglobulin format |
| EP2900696A1 (en) * | 2012-09-25 | 2015-08-05 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
-
2015
- 2015-07-21 AR ARP150102301A patent/AR101262A1/es active IP Right Grant
- 2015-07-23 TW TW104123813A patent/TWI704155B/zh active
- 2015-07-24 EP EP21170436.6A patent/EP3912987B9/en active Active
- 2015-07-24 PL PL21170436.6T patent/PL3912987T3/pl unknown
- 2015-07-24 WO PCT/US2015/041936 patent/WO2016018740A2/en not_active Ceased
- 2015-07-24 SG SG10201900661YA patent/SG10201900661YA/en unknown
- 2015-07-24 JP JP2017525320A patent/JP6702967B2/ja active Active
- 2015-07-24 FI FIEP21170436.6T patent/FI3912987T3/fi active
- 2015-07-24 MY MYPI2017700080A patent/MY187051A/en unknown
- 2015-07-24 EP EP15750182.6A patent/EP3172221B1/en active Active
- 2015-07-24 DK DK15750182.6T patent/DK3172221T3/da active
- 2015-07-24 EA EA201790247A patent/EA036154B1/ru not_active IP Right Cessation
- 2015-07-24 US US14/808,171 patent/US10626142B2/en active Active
- 2015-07-24 KR KR1020177003803A patent/KR102440737B1/ko active Active
- 2015-07-24 AU AU2015298156A patent/AU2015298156B2/en active Active
- 2015-07-24 ES ES15750182T patent/ES2881026T3/es active Active
- 2015-07-24 CN CN201580040494.9A patent/CN107074906B/zh active Active
- 2015-07-24 MX MX2017001217A patent/MX377558B/es active IP Right Grant
- 2015-07-24 PL PL15750182T patent/PL3172221T3/pl unknown
- 2015-07-24 SG SG11201700157VA patent/SG11201700157VA/en unknown
- 2015-07-24 DK DK21170436.6T patent/DK3912987T3/da active
- 2015-07-24 ES ES21170436T patent/ES2942533T3/es active Active
-
2017
- 2017-01-25 ZA ZA2017/00622A patent/ZA201700622B/en unknown
- 2017-10-22 IL IL255198A patent/IL255198B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101262A1 (es) | Plataforma de purificación para anticuerpos biespecíficos | |
| AR134186A2 (es) | Un anticuerpo anti-csf-1r, un proceso para producirlo, una composición farmacéutica que lo comprende, una secuencia de adn aislado, un vector de expresión o clonación y una célula hospedadora | |
| ECSP17083779A (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos | |
| CL2021001179A1 (es) | Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596). | |
| DOP2018000012A (es) | Anticuerpos específicos para tau hiperfosforilada y métodos de uso de los mismos | |
| CO2020000214A2 (es) | Anticuerpos agonistas que se unen a cd137 humano y sus usos | |
| MX2019006954A (es) | Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137). | |
| CO2018004743A2 (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
| MX2019006955A (es) | Terapia de combinacion con agonistas de 4-1bb orientados (cd137). | |
| CL2018000353A1 (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
| UY37635A (es) | Anticuerpos anti phf-tau y sus usos | |
| BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
| EA201890013A1 (ru) | Способы получения tcr гамма дельтат-клеток | |
| CO2017000300A2 (es) | Moléculas con especificidad para cd45 y cd79 | |
| MX2018004515A (es) | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. | |
| MX2017012679A (es) | Polipeptidos que contienen dominios de union de novo y usos de los mismos. | |
| CR20170079A (es) | Agentes de unión a cd123 y usos de estos | |
| MX395149B (es) | Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer. | |
| MX2022001085A (es) | Anticuerpos anti-c1s humanizados y metodos para usarlos. | |
| MX2018003827A (es) | Anticuerpos anti-cd19 humano con alta afinidad. | |
| MX2017013413A (es) | Compuestos de pirazol y metodo para elaborar y usar los compuestos. | |
| MX2017002205A (es) | Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer. | |
| CY1125938T1 (el) | Θεραπεια με βλαστοκυτταρα σε παθολογιες του ενδομητριου | |
| UY36678A (es) | Anticuerpos anti-fcrn. | |
| EA201690992A1 (ru) | Антитела, специфичные к fcrn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FG | Grant, registration |